BioAscent Discovery Ltd.

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services. Our expert scientists provide medicinal chemistry, in vitro biosciences and compound management services from our base in the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse,Scotland, and via Compound Cloud we offer access to an IP-free compound library in assay ready format.


Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management (>100 biochemical and biophysical assays established for drug discovery projects, >50 hit validation/characterisation projects, and >25 hit-to-lead campaigns since 2013).

Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications.

We currently hold and manage over 1 million compounds for our customers in our €20 million facility, storing and managing customer libraries ranging in size from a few thousand to a few hundred thousand compounds in both liquid and solid formats. We constantly receive and aggregate new compounds from our customers and their chemistry CRO partners, and ship in the assay-ready format of choice to their screening laboratories Via our Compound Cloud service, we provide rapid access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Our expertise in cherry picking, reformatting, shipping and data management have allowed us to deliver over 80,000 screening plates globally to our customers and their partner testing laboratories since 2013.

We are located in modern purpose-built laboratories on a single site, the former Organon / Merck Sharpe and Dohme (MSD) research & development facility, based within the BioCity Scotland campus at Newhouse, Scotland, UK.


Bo'ness Road